Amyvid florbetapir: Clinical trial data
A study in 618 patients being evaluated for cognitive decline showed that PET imaging with Amyvid led to treatment management changes in 68% of patients in the immediate-feedback group vs. 56% of patients in the delayed-feedback group. In the study, patients seeking diagnosis for mild impairment or dementia were identified and physicians recorded a working diagnosis and management plan. Patients underwent an Amyvid PET scan and were then randomized to an immediate-feedback group in which their physician received scan results 3 months later or a delayed-feedback group in which their physician received scan results 1 year later. After 3 months, patients returned and their physician updated the diagnosis and recorded an actual management summary. After 1 year, patients returned for assessment of patient and caregiver outcomes, including changes in cognitive status, health outcomes/resource utilization, mood, function and quality of life (QOL). ...